Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Progressive Medical Research
1136
mi
from
Port Orange, FL
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Progressive Medical Research
1136
mi
from
Port Orange, FL
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Columbus Regional Research Institute
807
mi
from
Columbus, GA
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Columbus Regional Research Institute
807
mi
from
Columbus, GA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Southeast Regional Res Group
1023
mi
from
Savannah, GA
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Southeast Regional Res Group
1023
mi
from
Savannah, GA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Centex Studies, Inc.
mi
from
Lake Charles, LA
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Centex Studies, Inc.
mi
from
Lake Charles, LA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
The Clinical Research Center, LLC
403
mi
from
Saint Louis, MO
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
The Clinical Research Center, LLC
403
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Comprehensive Clinical Research
1237
mi
from
Berlin, NJ
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Comprehensive Clinical Research
1237
mi
from
Berlin, NJ
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
ISA Clinical Research
1297
mi
from
Jamaica, NY
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
ISA Clinical Research
1297
mi
from
Jamaica, NY
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Clinical Research Inst. of Southern Oregon, PC
1357
mi
from
Medford, OR
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Clinical Research Inst. of Southern Oregon, PC
1357
mi
from
Medford, OR
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
S. Carolina Pharmaceutical Research
901
mi
from
Spartanburg, SC
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
S. Carolina Pharmaceutical Research
901
mi
from
Spartanburg, SC
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Centex Studies Inc
586
mi
from
Houston, TX
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Centex Studies Inc
586
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Western Washington Medical Group
1413
mi
from
Everett, WA
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Western Washington Medical Group
1413
mi
from
Everett, WA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Premier Clinical Research
1202
mi
from
Spokane, WA
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Premier Clinical Research
1202
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
MultiCare Health Center of Washington
1407
mi
from
Tacoma, WA
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
MultiCare Health Center of Washington
1407
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Centro Médico Dra de Salvo
mi
from
Buenos Aires,
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Centro Médico Dra de Salvo
mi
from
Buenos Aires,
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Phoenix Medical Research Institute, LLC; Phoenix Medical Research Institute, LLC
857
mi
from
Peoria, AZ
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Phoenix Medical Research Institute, LLC; Phoenix Medical Research Institute, LLC
857
mi
from
Peoria, AZ
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Gastonia Pharmaceutical Research
938
mi
from
Gastonia, NC
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Gastonia Pharmaceutical Research
938
mi
from
Gastonia, NC
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Piedmont Research Partners, LLC
962
mi
from
Indian Land, SC
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Piedmont Research Partners, LLC
962
mi
from
Indian Land, SC
Click here to add this to my saved trials
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated:  9/5/2017
Baylor College of Medicine; Ben Taub Hospital- Guntupalli
569
mi
from
Houston, TX
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
Status: Enrolling
Updated: 9/5/2017
Baylor College of Medicine; Ben Taub Hospital- Guntupalli
569
mi
from
Houston, TX
Click here to add this to my saved trials
Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers
A Pilot Study Evaluating the Effect of Pioglitazone, Simvastatin, and Ibuprofen on Neutrophil Migration in Vivo in Healthy Subjects
Status: Enrolling
Updated:  9/6/2017
University Hospitals of Cleveland
899
mi
from
Cleveland, OH
Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers
A Pilot Study Evaluating the Effect of Pioglitazone, Simvastatin, and Ibuprofen on Neutrophil Migration in Vivo in Healthy Subjects
Status: Enrolling
Updated: 9/6/2017
University Hospitals of Cleveland
899
mi
from
Cleveland, OH
Click here to add this to my saved trials
Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers
A Pilot Study Evaluating the Effect of Pioglitazone, Simvastatin, and Ibuprofen on Neutrophil Migration in Vivo in Healthy Subjects
Status: Enrolling
Updated:  9/6/2017
Rainbow Babies and Children's Hospital
899
mi
from
Cleveland, OH
Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers
A Pilot Study Evaluating the Effect of Pioglitazone, Simvastatin, and Ibuprofen on Neutrophil Migration in Vivo in Healthy Subjects
Status: Enrolling
Updated: 9/6/2017
Rainbow Babies and Children's Hospital
899
mi
from
Cleveland, OH
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
Mayo Clinic Scottsdale
835
mi
from
Scottsdale, AZ
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
Mayo Clinic Scottsdale
835
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
Stanford University
1329
mi
from
Stanford, CA
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
Stanford University
1329
mi
from
Stanford, CA
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
H. Lee Moffitt Cancer Center & Research Institute
1112
mi
from
Tampa, FL
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
H. Lee Moffitt Cancer Center & Research Institute
1112
mi
from
Tampa, FL
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
National Cancer Institute Experimental Transplantation & Immunology Branch
1123
mi
from
Bethesda, MD
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
National Cancer Institute Experimental Transplantation & Immunology Branch
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
Siteman Cancer Center at Washington University
414
mi
from
Saint Louis, MO
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
Siteman Cancer Center at Washington University
414
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
Vanderbilt University
618
mi
from
Nashville, TN
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
Vanderbilt University
618
mi
from
Nashville, TN
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
1410
mi
from
Seattle, WA
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
Medical College of Wisconsin
636
mi
from
Milwaukee, WI
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
Medical College of Wisconsin
636
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated:  9/6/2017
Weill-Cornell Medical College
1289
mi
from
New York, NY
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
Status: Enrolling
Updated: 9/6/2017
Weill-Cornell Medical College
1289
mi
from
New York, NY
Click here to add this to my saved trials
EAA Intake to Optimize Protein Anabolism in COPD
Essential Amino Acid Intake to Optimize Protein Anabolism in Elderly COPD Patients
Status: Enrolling
Updated:  9/7/2017
University of Arkansas for Medical Sciences
370
mi
from
Little Rock, AR
EAA Intake to Optimize Protein Anabolism in COPD
Essential Amino Acid Intake to Optimize Protein Anabolism in Elderly COPD Patients
Status: Enrolling
Updated: 9/7/2017
University of Arkansas for Medical Sciences
370
mi
from
Little Rock, AR
Click here to add this to my saved trials
The Effect of Thiamine vs. Placebo on VO2 in Critical Illness
The Effect of Thiamine vs. Placebo on VO2 in Critical Illness
Status: Enrolling
Updated:  9/7/2017
Beth Israel Deaconess Medical Center
1444
mi
from
Boston, MA
The Effect of Thiamine vs. Placebo on VO2 in Critical Illness
The Effect of Thiamine vs. Placebo on VO2 in Critical Illness
Status: Enrolling
Updated: 9/7/2017
Beth Israel Deaconess Medical Center
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers
Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers
Status: Enrolling
Updated:  9/7/2017
Kansas University Medical Center
196
mi
from
Kansas City, KA
Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers
Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers
Status: Enrolling
Updated: 9/7/2017
Kansas University Medical Center
196
mi
from
Kansas City, KA
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
1161
mi
from
Newport Beach, CA
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
1161
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
1135
mi
from
Upland, CA
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
1135
mi
from
Upland, CA
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
604
mi
from
Sunset, LA
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
604
mi
from
Sunset, LA
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
957
mi
from
Charlotte, NC
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
957
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
727
mi
from
Cincinnati, OH
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
727
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
1357
mi
from
Medford, OR
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
1357
mi
from
Medford, OR
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
916
mi
from
Gaffney, SC
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
916
mi
from
Gaffney, SC
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
883
mi
from
Greenville, SC
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
883
mi
from
Greenville, SC
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
953
mi
from
Rock Hill, SC
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
953
mi
from
Rock Hill, SC
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
902
mi
from
Spartanburg, SC
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
902
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
929
mi
from
Union, SC
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
929
mi
from
Union, SC
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
970
mi
from
Morgantown, WV
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
970
mi
from
Morgantown, WV
Click here to add this to my saved trials
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated:  9/7/2017
GSK Investigational Site
5602
mi
from
Ciudad Autonoma de Buenos Aires,
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD
Status: Enrolling
Updated: 9/7/2017
GSK Investigational Site
5602
mi
from
Ciudad Autonoma de Buenos Aires,
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
649
mi
from
Jasper, AL
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
649
mi
from
Jasper, AL
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
854
mi
from
Glendale, AZ
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
854
mi
from
Glendale, AZ
Click here to add this to my saved trials
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
1160
mi
from
Fountain Valley, CA
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
1160
mi
from
Fountain Valley, CA
Click here to add this to my saved trials